01  The Pitch in One Breath

Molbio Diagnostics Limited was incorporated on 20 October 2000 and is headquartered at Verna, South Goa. The prospectus describes it as a point-of-care (POC) diagnostics company focused on making accurate, rapid and cost-effective testing available for infectious and non-communicable diseases.

The flagship is Truenat, a battery-operated POC polymerase chain reaction (PCR) platform designed to work in resource-limited settings and deliver a diagnosis within an hour. As of 31 March 2026 the company offered molecular tests for 30 diseases through 43 assays, including tuberculosis (TB), COVID, hepatitis B and C, HIV and HPV, and had exported to more than 90 countries. Two subsidiaries widen the portfolio: Prognosys (ProRad digital X-ray systems, plus veterinary imaging) and OptraScan (digital pathology scanners and AI-assisted analysis).

02  The Market It Plays In

The RHP leans on an industry report by 1Lattice (a third-party report cited in the filing, so treat it as the issuer’s chosen lens). It sizes the global POC testing market, measured by tests conducted, at USD 29.3 billion, growing at a 17.9% CAGR between 2025 and 2030 to USD 67.1 billion. Infectious disease testing is about 32.6% of that market, and within it TB is the largest contributor, followed by HPV, hepatitis C, hepatitis B and sexually transmitted infections.

That last line matters for what follows: the segment where the market is deepest is also the segment where Molbio’s revenue is most concentrated.

03  Under the Hood: How Truenat Works

Truenat is a two-box system. Trueprep AUTO V2 is a fully automatic, cartridge-based sample-prep device that extracts and purifies DNA/RNA. Truelab is a real-time, quantitative micro-PCR analyser that reads disease-specific micro-PCR chips. Sample to result takes about an hour, per the company website.

What the engineering is really solving

Read the feature list as a response to constraints, not a spec sheet. Battery operation and an optional solar unit (Truelux) remove the power dependency. Random access means a clinic can run one sample at a time instead of waiting to fill a batch. Automated extraction and interpretation cut the training burden. And the cartridge-and-chip format keeps the molecular chemistry inside consumables, which is what makes the model repeatable (see next section).

On breadth, the website says Truenat is patented in more than 100 countries, supports 40+ assays, and has been used in outbreaks including H1N1 (2015), chikungunya (2016), COVID-19 (2020) and Nipah (2021). The RHP also states an intention to add 34 further assays covering 22 diseases, which would take the menu well beyond today’s 43.

04  The Business Model: Razors, Blades and Tenders

Molbio sells the instrument (the “razor”) once and the chip, cartridge and reagent kit (the “blade”) repeatedly. The financials show how lopsided that split has become:

Test kits were about 72% of FY26 revenue from operations (derived), devices about 14%. Kit volumes grew 43.5% in FY26 against device unit growth of 15.8%, which is the installed-base flywheel doing its job: more devices in the field, more kits pulled through them.

05  The Numbers: Three Years, One Table

Revenue compounded at roughly 31.5% a year over FY24–FY26 (derived), accelerating from +22.0% in FY25 to +41.7% in FY26. Profit growth was lumpier: +65.9% in FY25 but +18.4% in FY26, so profit grew at less than half the pace of sales last year. EBITDA margin gave back about 2.4 percentage points and ROCE fell from 20.98% to 17.55%.

One mitigating detail: the company spends on R&D through its subsidiary Bigtec, and the filing’s “EBITDA pre-R&D” line lets us back out the spend (derived): about ₹59.8 cr, ₹68.6 cr and ₹87.5 cr in FY24, FY25 and FY26. R&D grew 27.5% in FY26 yet fell from 6.7% to 6.1% of revenue from operations, so the margin squeeze is not simply a story of heavier R&D.

06  Earnings Quality and the Balance Sheet

Cash conversion is the weakest part of the picture. Operating cash flow swung from ₹9.6 cr to ₹287.1 cr to ₹50.4 cr. Across the three years it totals about ₹347 cr against about ₹386 cr of profit, roughly 90% conversion (derived), but FY26 alone converted only about 31%. In the same year borrowings more than tripled to ₹412.6 cr and financing brought in ₹276 cr. Even so, leverage is modest: borrowings are about 0.36× net worth and about 1.3× EBITDA (derived).

The prospectus also lists, among its top risks, that the consolidated company and some subsidiaries have had negative operating cash flows in the past, and that there have been instances of delays in paying statutory dues. Both are standard line items to track in subsequent filings.

07  The Elephant in the Lab: Concentration

This is the section the RHP itself puts at the top of its risk list, and the numbers justify it.

Three points stand out. First, dependence on public-health buyers is easing, from 91.6% to 84.6%, but remains very high. Second, the portfolio looks diversified on paper (30 diseases) while the money is not: TB kits generated ₹982.0 cr in FY26 (+44.4%) versus ₹52.8 cr for every other disease combined (+3.4%) (derived). Third, geography has tilted back home: India was 90.4% of FY26 revenue (80.7% in FY25), while overseas revenue fell from ₹197.1 cr to ₹139.0 cr, about −29.5% (derived).

08  Capacity, R&D and Where the IPO Money Goes

The company operates six manufacturing sites: two in Verna (Goa) making Truenat test kits, one in Visakhapatnam (devices and kit components), one in Peenya, Bengaluru (kit components), plus subsidiary sites at Machohalli, Bengaluru (ProRad devices, Prognosys) and Pune (digital pathology scanners, OptraScan India).

The offer, which ran from 10 to 12 August 2026 with an anchor book on 7 August, combines a fresh issue of ₹200 crore with an offer for sale of up to 91.66 lakh shares (about 8.1% of pre-offer shares, derived). The company receives money only from the fresh issue; selling shareholders receive the OFS proceeds. Face value is ₹1 per share, listing is proposed on NSE and BSE, and the book-running lead managers are Kotak Mahindra Capital, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors.

About ₹178 crore of the ₹200 crore is earmarked for capex, so the fresh issue is a build-out story rather than a debt-repayment one. That squares with the strategy list in the filing: more geographies, more diseases, new POC platforms, and a Centre of Excellence.

09  People, Promoters and the Fine Print

Promoters are Sriram Natarajan (Executive Director and CEO), Dr. Chandrasekhar Bhaskaran Nair (Executive Director and CTO, and a recipient of the Infosys Prize 2021 in engineering and computer science), Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP, a family office and investment entity. The board has six members: three executive directors and three independent directors (Dr. Arun Kumar Jha, Dr. Balram Bhargava and Nupur Garg). The CFO is Manan Bimal Khokhani.

Capital structure changed materially before filing: shares were split from ₹10 to ₹1 face value in July 2024, and a 4-for-1 bonus was allotted on 29 July 2025. Promoters Exxora and Dr. Nair are also selling shareholders in the OFS (up to 18.11 lakh and 12.21 lakh shares respectively).

Litigation snapshot (as disclosed in the RHP)

The filing reports no material civil litigation and no disciplinary action by SEBI or the exchanges against the promoters in the last five years. On the audit side, there is no qualification requiring corrective adjustment to the restated numbers. However, the FY24 audit report carries an emphasis-of-matter paragraph, and the FY24–FY26 reports include modifications under the CARO reporting requirements and Rule 11(g). None required adjustment, but the filing flags them as a risk factor and they deserve a read in the MD&A section on auditor observations.

10  The Scorecard: What Works, What to Watch

11  Five Questions for the Next Filing

• Did non-TB test-kit revenue start to move, and which of the 34 planned assays reached commercial launch?

• Is the decline in realisation per kit and per device a mix effect or a pricing effect?

• Did operating cash flow catch up with profit, and what happened to receivable days from government buyers?

• How are Bigtec’s R&D facility and the Goa/Visakhapatnam capacity additions progressing against the cost estimates in the Objects of the Offer?

• What drove the drop in overseas revenue, and is it timing of tenders or a structural shift?

Reader note: financial figures, KPIs, risk disclosures, objects of the offer, shareholding and litigation counts are taken from the Abridged Prospectus, which summarises the RHP; page references in the RHP are given there. Figures marked “derived” are simple calculations on those numbers. Data is as of the RHP date and fiscal year ended 31 March 2026; later quarterly results and market prices are not covered. This article is informational and is not investment advice or a recommendation to buy, sell or hold any security.